Glaukos Corp
$ 126.34
3.59%
09 Jun - close price
- Market Cap 7,163,188,000 USD
- Current Price $ 126.34
- High / Low $ 129.00 / 123.58
- Stock P/E N/A
- Book Value 11.50
- EPS -3.31
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.26 %
- 52 Week High 148.11
- 52 Week Low 73.16
About
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Analyst Target Price
$154.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-29 | 2026-02-17 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-20 | 2024-11-04 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 | 2023-08-02 |
| Reported EPS | -0.18 | -0.9 | -0.16 | -0.24 | -0.22 | -0.4 | -0.28 | -0.52 | -0.7 | -0.63 | -0.5 | -0.55 |
| Estimated EPS | -0.28 | -0.21 | -0.26 | -0.26 | -0.35 | -0.3885 | -0.48 | -0.51 | -0.57 | -0.55 | -0.55 | -0.56 |
| Surprise | 0.1 | -0.69 | 0.1 | 0.02 | 0.13 | -0.0115 | 0.2 | -0.01 | -0.13 | -0.08 | 0.05 | 0.01 |
| Surprise Percentage | 35.7143% | -328.5714% | 38.4615% | 7.6923% | 37.1429% | -2.9601% | 41.6667% | -1.9608% | -22.807% | -14.5455% | 9.0909% | 1.7857% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GKOS
2026-06-07 15:09:49
Glaukos Corp's balance sheet for Q1 2026 shows total assets of 773.19 million EUR, a decrease of 2.39% from Q4 2025. Total liabilities also decreased significantly by 17.55% to 192.49 million EUR in the same quarter. The report provides a historical view of assets and liabilities and allows for a comparison between annual and quarterly metrics.
2026-06-06 17:11:36
This page provides key financial statistics and ratios for Glaukos Corp (XETR:6GJ), including valuation, profitability, liquidity, and solvency metrics. Users can access annual and quarterly data for various financial indicators like P/E ratio, EPS, and ROI, though most data fields are currently displayed as "—". It serves as a go-to hub for investors interested in the company's financial health.
2026-06-06 16:09:20
This article provides financial data for Glaukos Corp (XETR:6GJ), focusing on its cash flow activities. It reports the free cash flow for Q1 2026 was -14.27 million EUR and for the full year 2025 was -33.26 million EUR, with operating cash flow at -12.59 million EUR. The data includes historical annual and quarterly metrics for operating, investing, and financing cash flows.
2026-06-06 16:09:20
Glaukos Corp reported total revenue of €432.05 million last year, with its Glaucoma segment being the primary contributor at €358.51 million. The majority of this revenue, €319.32 million, was generated from sales in the United States. This indicates a strong focus and performance in the glaucoma market within the US.
2026-06-05 18:39:38
Glaukos (GKOS) shows strong growth potential due to its iDose TR and Epioxa products, diversified ophthalmology portfolio, and positive earnings surprise history. However, the company faces challenges including reimbursement hurdles for Epioxa, increased competition in international glaucoma markets, and vulnerability in its core U.S. glaucoma business. Despite these risks, the company's long-term revenue visibility and pipeline suggest it could be a valuable stock to retain.
2026-06-04 13:52:00
This article analyzes Glaukos Corporation (GKOS), noting divergent sentiment and choppy conditions. It highlights a precise short setup with an exceptional 51.7:1 risk-reward ratio, targeting a 14.9% downside. The piece also details various AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
